KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Receivables: 2009-2024

Historic Receivables for Quest Diagnostics (DGX) over the last 16 years, with Dec 2024 value amounting to $1.3 billion.

  • Quest Diagnostics' Receivables rose 5.81% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 billion, marking a year-over-year increase of 6.81%. This contributed to the annual value of $1.3 billion for FY2024, which is 7.77% up from last year.
  • Latest data reveals that Quest Diagnostics reported Receivables of $1.3 billion as of FY2024, which was up 7.77% from $1.2 billion recorded in FY2023.
  • Over the past 5 years, Quest Diagnostics' Receivables peaked at $1.5 billion during FY2020, and registered a low of $1.2 billion during FY2022.
  • For the 3-year period, Quest Diagnostics' Receivables averaged around $1.2 billion, with its median value being $1.2 billion (2023).
  • As far as peak fluctuations go, Quest Diagnostics' Receivables soared by 42.74% in 2020, and later decreased by 16.90% in 2022.
  • Over the past 5 years, Quest Diagnostics' Receivables (Yearly) stood at $1.5 billion in 2020, then declined by 5.58% to $1.4 billion in 2021, then decreased by 16.90% to $1.2 billion in 2022, then grew by 1.26% to $1.2 billion in 2023, then rose by 7.77% to $1.3 billion in 2024.